These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36535106)

  • 1. Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis.
    Schraad M; Uphaus T; Runkel S; Hitzler W; Bittner S; Zipp F
    EBioMedicine; 2023 Jan; 87():104411. PubMed ID: 36535106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
    Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
    Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders.
    Algu P; Hameed N; DeAngelis T; Stern J; Harel A
    Mult Scler Relat Disord; 2023 Nov; 79():104965. PubMed ID: 37657307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Observation of SARS-CoV-2 Vaccination Response upon High Efficacy Treatment in Multiple Sclerosis-A Real-World Scenario.
    Schraad M; Runkel S; Hitzler W; Protopapa M; Bittner S; Uphaus T; Zipp F
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
    Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
    Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study.
    Krajnc N; Hegen H; Traxler G; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Riedl K; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T; Bsteh G
    Mult Scler Relat Disord; 2022 Sep; 65():104009. PubMed ID: 35797803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment.
    Woopen C; Dunsche M; Haase R; Raposo C; Pedotti R; Akgün K; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
    Conte WL
    Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
    Proschmann U; Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dillenseger A; Dunsche M; Atta Y; Ziemssen T; Akgün K
    Mult Scler; 2023 Dec; 29(14):1849-1859. PubMed ID: 37776101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
    Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
    Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
    Stoll S; Desai S; Levit E
    Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
    Wu X; Wang L; Shen L; Tang K
    EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
    Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
    EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
    J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis.
    Kanakura M; Kihara K; Kinoshita M; Sugimoto T; Murata H; Beppu S; Shiraishi N; Sugiyama Y; Koda T; Takahashi MP; Chinen I; Okuno T; Mochizuki H
    Clin Neurol Neurosurg; 2024 Aug; 243():108378. PubMed ID: 38901377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
    Schwarz T; Otto C; Jones TC; Pache F; Schindler P; Niederschweiberer M; Schmidt FA; Drosten C; Corman VM; Ruprecht K
    Mult Scler; 2022 Jun; 28(7):1041-1050. PubMed ID: 35575234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.
    Etemadifar M; Sedaghat N; Nouri H; Lotfi N; Chitsaz A; Khorvash R; Zolfaghari H; Ghasemi Movaghar A; Pourabbas M; Salari M
    Mult Scler Relat Disord; 2022 Jan; 57():103417. PubMed ID: 34875487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.